Literature DB >> 28811979

PD-L1 blockade for urothelial carcinoma.

Josephine Kang1, Lorenzo Galluzzi1,2,3.   

Abstract

Entities:  

Year:  2017        PMID： 28811979      PMCID： PMC5543828          DOI： 10.1080/2162402X.2017.1334028

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN： 2162-4011            Impact factor:   8.110


× No keyword cloud information.
  14 in total

1.  The safety and efficacy of single-agent pemetrexed in platinum-resistant advanced urothelial carcinoma: a large single-institution experience.

Authors:  Richard M Bambury; David J Benjamin; Joshua L Chaim; Emily C Zabor; John Sullivan; Ilana R Garcia-Grossman; Ashley M Regazzi; Irina Ostrovnaya; Aryln Apollo; Han Xiao; Martin H Voss; Gopa Iyer; Dean F Bajorin; Jonathan E Rosenberg
Journal:  Oncologist       Date:  2015-04-06

2.  Phase II trial of weekly paclitaxel in patients with previously treated advanced urothelial cancer.

Authors:  David J Vaughn; Catherine M Broome; Maha Hussain; John C Gutheil; Avi B Markowitz
Journal:  J Clin Oncol       Date:  2002-02-15       Impact factor: 44.544

3.  Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial.

Authors:  Padmanee Sharma; Margitta Retz; Arlene Siefker-Radtke; Ari Baron; Andrea Necchi; Jens Bedke; Elizabeth R Plimack; Daniel Vaena; Marc-Oliver Grimm; Sergio Bracarda; José Ángel Arranz; Sumanta Pal; Chikara Ohyama; Abdel Saci; Xiaotao Qu; Alexandre Lambert; Suba Krishnan; Alex Azrilevich; Matthew D Galsky
Journal:  Lancet Oncol       Date:  2017-01-26       Impact factor: 41.316

4.  Cancer Statistics, 2017.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2017-01-05       Impact factor: 508.702

5.  Phase II study of pemetrexed for second-line treatment of transitional cell cancer of the urothelium.

Authors:  Christopher J Sweeney; Bruce J Roth; Fairooz F Kabbinavar; David J Vaughn; Michael Arning; Rafael E Curiel; Coleman K Obasaju; Yanping Wang; Steven J Nicol; Donald S Kaufman
Journal:  J Clin Oncol       Date:  2006-07-20       Impact factor: 44.544

6.  Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial.

Authors:  Jonathan E Rosenberg; Jean Hoffman-Censits; Tom Powles; Michiel S van der Heijden; Arjun V Balar; Andrea Necchi; Nancy Dawson; Peter H O'Donnell; Ani Balmanoukian; Yohann Loriot; Sandy Srinivas; Margitta M Retz; Petros Grivas; Richard W Joseph; Matthew D Galsky; Mark T Fleming; Daniel P Petrylak; Jose Luis Perez-Gracia; Howard A Burris; Daniel Castellano; Christina Canil; Joaquim Bellmunt; Dean Bajorin; Dorothee Nickles; Richard Bourgon; Garrett M Frampton; Na Cui; Sanjeev Mariathasan; Oyewale Abidoye; Gregg D Fine; Robert Dreicer
Journal:  Lancet       Date:  2016-03-04       Impact factor: 79.321

Review 7.  Trial Watch: Immunostimulation with Toll-like receptor agonists in cancer therapy.

Authors:  Kristina Iribarren; Norma Bloy; Aitziber Buqué; Isabelle Cremer; Alexander Eggermont; Wolf Hervé Fridman; Jitka Fucikova; Jérôme Galon; Radek Špíšek; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2015-09-02       Impact factor: 8.110

8.  Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer.

Authors:  Christophe Massard; Michael S Gordon; Sunil Sharma; Saeed Rafii; Zev A Wainberg; Jason Luke; Tyler J Curiel; Gerardo Colon-Otero; Omid Hamid; Rachel E Sanborn; Peter H O'Donnell; Alexandra Drakaki; Winston Tan; John F Kurland; Marlon C Rebelatto; Xiaoping Jin; John A Blake-Haskins; Ashok Gupta; Neil H Segal
Journal:  J Clin Oncol       Date:  2016-06-06       Impact factor: 44.544

9.  Robust detection of immune transcripts in FFPE samples using targeted RNA sequencing.

Authors:  Benjamin E Paluch; Sean T Glenn; Jeffrey M Conroy; Antonios Papanicolau-Sengos; Wiam Bshara; Angela R Omilian; Elizabeth Brese; Mary Nesline; Blake Burgher; Jonathan Andreas; Kunle Odunsi; Kevin Eng; Ji He; Maochun Qin; Mark Gardner; Lorenzo Galluzzi; Carl D Morrison
Journal:  Oncotarget       Date:  2017-01-10

10.  Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial.

Authors:  Padmanee Sharma; Margaret K Callahan; Petri Bono; Joseph Kim; Pavlina Spiliopoulou; Emiliano Calvo; Rathi N Pillai; Patrick A Ott; Filippo de Braud; Michael Morse; Dung T Le; Dirk Jaeger; Emily Chan; Chris Harbison; Chen-Sheng Lin; Marina Tschaika; Alex Azrilevich; Jonathan E Rosenberg
Journal:  Lancet Oncol       Date:  2016-10-09       Impact factor: 41.316
View more
  5 in total

Review 1.  Trial Watch: Toll-like receptor agonists in cancer immunotherapy.

Authors:  Melody Smith; Elena García-Martínez; Michael R Pitter; Jitka Fucikova; Radek Spisek; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2018-10-11       Impact factor: 8.110

Review 2.  Trial watch: DNA-based vaccines for oncological indications.

Authors:  Stefano Pierini; Renzo Perales-Linares; Mireia Uribe-Herranz; Jonathan G Pol; Laurence Zitvogel; Guido Kroemer; Andrea Facciabene; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2017-11-20       Impact factor: 8.110

Review 3.  Trial watch: Peptide-based vaccines in anticancer therapy.

Authors:  Lucillia Bezu; Oliver Kepp; Giulia Cerrato; Jonathan Pol; Jitka Fucikova; Radek Spisek; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2018-09-06       Impact factor: 8.110

4.  PD-L2 amplification and durable disease stabilization in patient with urothelial carcinoma receiving pembrolizumab.

Authors:  Saby George; Antonios Papanicolau-Sengos; Felicia L Lenzo; Jeffrey M Conroy; Mary Nesline; Sarabjot Pabla; Sean T Glenn; Blake Burgher; Jonathan Andreas; Vincent Giamo; Moachun Qin; Yirong Wang; Lorenzo Galluzzi; Carl Morrison
Journal:  Oncoimmunology       Date:  2018-05-29       Impact factor: 8.110

5.  The predictive value of energy spectral CT parameters for assessing Ki-67 expression of lung cancer.

Authors:  Yankai Meng; Kai Xu; Peipei Dou; Zhongxiao Liu; Lixiang Xie; Chong Meng; Chen Wang; Yingying Cui; Chunfeng Hu; Guangjun Cheng; Jyhcheng Chen
Journal:  Transl Cancer Res       Date:  2020-07       Impact factor: 1.241
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.